MedTrace Logo

Contrasting the Brain Effects of Risperidone and Invega With Functional Magnetic Resonance Imaging (fMRI) and Positron Emission Tomography (PET) Scanning

NCT00937261 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 96

Last updated 2010-10-28

No results posted yet for this study

Summary

The purpose of this study is to better understand brain function and psychiatric and neurological illness when taking Invega or Risperdal. The objective is to compare the brain effects of Invega to Risperdal in patients with Schizophrenia. This comparison will be evaluated with PET imaging, fMRI, and neurological ratings and assessments.

Conditions

Interventions

DRUG

Risperidone

2mg - 8mg per day, for the duration of participation in the study

DRUG

Paliperidone

6mg - 12mg per day, for the duration of participation in the study

Sponsors & Collaborators

  • Janssen, LP

    collaborator INDUSTRY

  • University of California, Irvine

    lead OTHER

Principal Investigators

  • Steven G Potkin, M.D. · UC Irvine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-07-31
Primary Completion
2010-07-31
Completion
2011-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00937261 on ClinicalTrials.gov